Clinical Trial Update: Ceritinib Rare Indications Study in ALK+ Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for ceritinib in ALK-altered tumors including anaplastic large cell lymphoma and related conditions; study terminated with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Glioblastoma
• Inflammatory Myofibroblastic Tumor
• Tumors with Aberrations in Alk

Drugs mentioned

• Ceritinib (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2019-10-21